HiFiBiO Therapeutics has signed a deal with Japanese Big Pharma and its friend from the common sector, the Takeda company. Its goal is to develop antibody-based therapies for various gastrointestinal diseases, cancers and disorders of other types.
The HiFiBiO company conducts its works on antibodies through subjecting single B-cells (formerly called B-cells) to screening and an analysis.It collects funds for its research activity, development and milestone achievement from the delivery of antibodies to Takeda. The latter entity subjects them to further development and sales.
Both companies have recently confirmed that their scientists will work together on discovering further antibodies, using the capabilities of single cells.Takeda will assume responsibility for the preclinical and clinical development of said research.
The new CEO of HiFiBiO Liang Schweizer, Ph.D. - formerly occupying managerial positions at Sanofi and Bristol-Myers Squibb with regard to research on cancer - underlines that this partnership confirms the joint and continuous commitment to such types of open cooperation, intended to improve handling unmet medical needs all around the world.